RvD2 treatment partially prevents angiotensin II (Ang II)-induced hypertension, lowers blood pressure and vascular stiffness, reduces myocardial fibrosis, and decreases neutrophil infiltration [77]. The gene discussed is AGT; the disease is hypertensive disorder.